Abstract
Background
Pelvic inflammatory disease (PID) is common and can lead to tubal factor infertility, ectopic pregnancy or chronic pelvic pain. Despite major UK government investment in the National Chlamydia Screening Programme, evidence of benefit remains controversial. The main aim of this trial was to investigate whether screening and treatment of chlamydial infection reduced the incidence of PID over 12 months. Secondary aims were to conduct exploratory studies of the role of bacterial vaginosis (BV) in the development of PID and of the natural history of chlamydial infection.
Design
Randomised controlled trial with follow up after 12 months.
Setting non-healthcare
Common rooms and lecture theatres at 20 universities and further education colleges in Greater London.
Participants
2500 sexually active female students were asked to complete a questionnaire on sexual health and provide self-administered vaginal swabs and smears.
Intervention
Vaginal swabs from intervention women were tested for chlamydia by polymerase chain reaction (PCR) and those infected referred for treatment. Vaginal swabs from control women were stored and analysed after a year. Vaginal smears were Gram stained and analysed for BV.
Main outcome measure
Incidence of clinical PID over 12 months in intervention and control groups. Possible cases of PID will be identified from questionnaires and record searches. Confirmation of the diagnosis will be done by detailed review of medical records by three independent researchers blind to whether the woman is in intervention or control group.
Trial registration
Clinical Trials NCT 00115388
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 St George's, University of London, Division of Community Health Sciences, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X)
2 Imperial College, Department of Primary Care and Social Medicine, London, UK (GRID:grid.7445.2) (ISNI:0000000121138111)
3 Kings College London, Department of Health and Social Care Research, London, UK (GRID:grid.13097.3c) (ISNI:0000000123226764)
4 Imperial College School of Medicine, Department of Genitourinary Medicine and Communicable Diseases, St Mary's, London, UK (GRID:grid.7445.2) (ISNI:0000000121138111)
5 Centre for Infections, Health Protection Agency, London, UK (GRID:grid.271308.f) (ISNI:0000 0004 5909 016X)
6 St George's Hospital, Department of Genitourinary Medicine, London, UK (GRID:grid.464688.0) (ISNI:0000000123007844)




